The role of the serotonin 5-HT4 receptor in motor and non-motor symptoms of Parkinson’s disease

Información del proyecto

HT4PD

Identificador del acuerdo de subvención: 894207

DOI

10.3030/894207

Proyecto cerrado

Fecha de la firma de la CE 20 Marzo 2020

Fecha de inicio 1 Enero 2021

Fecha de finalización 31 Diciembre 2023

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total

€ 295 061,76

Aportación de la UE

€ 295 061,76

Coordinado por

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France

Periodic Reporting for period 1 - HT4PD (The role of the serotonin 5-HT4 receptor in motor and non-motor symptoms of Parkinson’s disease)

Período documentado: 2021-01-01 hasta 2023-12-31

Resumen del contexto y de los objetivos generales del proyecto

Parkinson’s Disease (PD) is the second most common, progressive, adult onset, neurodegenerative disease in Europe and is characterized by the loss of midbrain dopaminergic neurons and the formation of Lewy bodies in the remaining dopaminergic neurons, causing motor impairment such as bradykinesia, rigidity and slow movement. Dopamine (DA) via L-Dopa therapy ameliorates many but not all symptoms and induces uncontrollable L-Dopa induced dyskinesia (LID), a complicated and debilitating side effect that affects almost all patients following 5-10 years of chronic treatment. L-Dopa induced dyskinesia (LID) affects up to 90% of patients treated with L-DOPA and currently no treatment to ameliorate symptoms exist. There is an urgent need to better understand the pathophysiology underlying this important treatment side effect and to develop drugs to reduce symptoms.

It is known that the neurotransmitters systems of Dopamine and Serotonin interact with each other and it is known that neurons producing serotonin can also metabolize and release L-DOPA which Is thought to contribute to the L-DOPA induced dyskinesia.

We study specific serotonin receptors to better understand this functional interaction and to identify targets for pharmacotherapy aiming to alleviate the dyskinesia. We want to determine the expression pattern of serotonin receptors on a cellular level, determine how modulation thereof alters responses to the drug L-DOPA and to LID in a mouse model of Parkinson.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

We are in the process of studying the role a serotonin receptor in the context of L-DOPA induced dyskinesia and have shown that modulating receptor activity also impacts on the severity of L-DOPA induced dyskinesia.
We are currently investigating the molecular underpinnings of this functional interaction in a cell–specific context.

We have shown that pharmacological activation of 5-HT4 receptor activity reduces L-DOPA induced dyskinesia in a mouse model of Parkinson's disease. We further found that this activation does not impact negatively on the anti-akinetic effect of L-DOPA.
Using the RNAscope technology and qPCR, we show that the 5-HT4 receptor in the dorsal striatum is predominantly expressed in D2-receptor expressing medium spiny neurons (MSNs) and that its expression is enhanced in response to Dopamine depletion and L-DOPA treatment.
We therefore conclude that the anti-LID action of 5-HT4R agonssim is mediated via the D2-MSNs.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

This is the final report for the grant, but we plan to further investigate the role of this receptor in LID.

RNAscope for 6-OHDA lesioned striatum